| |
|
|
| |
Gardiner F.H. Smith is President and Chief Executive Officer
of ThermalTherapeutic Systems (TTS). Mr. Smith joined TTS after guiding several life sciences startups through the Pittsburgh Life
Sciences Greenhouse Executive Program. Prior to joining the Greenhouse, Mr. Smith was CEO and founder of TenX Biopharma, a Phase III
cancer antibody company which was sold in May, 2011. He previously co-founded a consulting firm, SHI Link, of 8 professionals offering
biopharma and medical device management services, including his position as interim President of Nexeon MedSystems. Mr. Smith's
executive experience includes serving as the SVP of business development at Aspreva Pharmaceuticals, and as the Chief Business Officer,
Memory Pharmaceuticals Corp where he played a key role in a 2004 IPO, raising $35 MM, and a 2005 PIPE for $20 MM. At Memory he led
four major transactions in three and a half years, providing $60 MM in payments made to the company resulting in later acquisition.
As Executive Director, Business Development, at Human Genome Sciences Inc., Mr. Smith led multiple transactions with small and large
pharmaceutical companies. Mr. Smith also served as the Director, International Licensing, Glaxo Wellcome where he supported the oncology
therapeutic franchise and genomics directorate and led strategic alliances with industry and academic centers.
Education:1992 Juris Doctorate, North Carolina Central University; 1983 Bachelor's, Chemistry, University of North Carolina at Chapel Hill.
|
|
Gardiner F.H. Smith
President and
Chief Executive Officer
|
|
|
|
|
| |
Joseph T. Donnelly,
a financial executive with 32 years of professional experience
in the healthcare industry, Joe began his career with Price Waterhouse.
He later joined Allegheny Health, Education & Research as
the Vice President and Corporate Controller and Chief Financial
Officer of Allegheny Singer Research Institute. Joe co-founded
Metamorphic Surgical Devices before the technology was acquired
by the Guidant Corporation. Most recently Joe served as Chief
Financial Officer of RedPath Integrated Pathology and Chief Financial
Officer for Vytrace Corporation. Joe serves on the Boards of
NSABP Foundation, a national research cooperative group that
conducts clinical trials for breast and colon cancer therapies,
and Axios Foundation, an international non-profit organization
focused on improving the healthcare delivery systems in developing
countries, particularly in Africa. |
|
Joseph T. Donnelly
Chief Financial Officer
|
|
|
|
|
| |
Michael S. Gronsky is Director of Operations of ThermalTherapeutic Systems.
Mike has 36 years of experience in the manufacturing and R&D of electromechanical devices. He was in
charge of Production and Inventory management at NOMOS Corporation. While there, he participated in the
development and manufacture of the first FDA cleared devices for Intensity Modulated Radiation Therapy
(IMRT) and ultrasound-based Image Guided Radiation Therapy (IGRT). Prior to that, Mike worked in Nuclear
Quality Control for Westinghouse Electric Corporation and in the R&D department of Rockwell International's
Measurement and Flow Control division.
|
|
Michael S. Gronsky
Director of Operations
|
|
|
|
|
| |
Barry J. Feldman is Director of Sales & Marketing for ThermalTherapeutic Systems.
Barry is known in the medical device industry for his combined technical and business expertise, and has been instrumental
in successfully introducing new technologies, including rapid infusers, fluid warming, anesthesia delivery systems,
cardiopulmonary, brain and gas monitors and a new cardioplegia solution. With 24 years of experience in various sales,
marketing and technical positions, and with a proven track record of success introducing new OR, ED and ICU technology and
driving market adoption, Barry's bioengineering and medical physiology background has played a key role in establishing a solid
reputation for outstanding customer support, education and training.
|
|
Barry J. Feldman
Director of Sales & Marketing
|
|
|
|
|
| |
|
|
| |
Peter M. DeComo is Chairman
and CEO of Alung Technologies, Inc., a company which is currently
developing a revolutionary Artificial Lung technology for the
treatment of respiratory failure. Pete is the former Founder,
Chairman and CEO of Renal Solutions, Inc. where he raised $40
million in private equity financing and $25 million in debt financing
to fund the development of Renal's innovative Allient®, sorbent-based hemodialysis system. Renal
Solutions was acquired by Fresenius Medical Care Holdings for $200
million in November, 2007. Pete also sits on the Board of ClearCount
Medical Solutions, the developer of the SmartSponge System™ which
utilizes RFID chip technology for the counting and tracking of
sponges during surgical procedures in the operating room. In addition,
he is a Director on the Boards of the Pittsburgh Life Science Greenhouse
and the Pittsburgh Technology Council.
|
|
Peter M. DeComo
Co-Founder and
Chairman of the Board
|
|
|
|
|
| |
Mary Del Brady is a serial
entrepreneur with more than thirty years of experience in building
companies in the services and biotechnology industries for which
she has raised more than $25 million in seed and venture capital. Mary
Del was founding CEO of RedPath Integrated Pathology, Inc. which
recently sold to ExonHit Therapeutics, S.A., a leading French diagnostics
and therapeutics biotech company, and Co-Founder and President
of TissueInformatics.Inc, later acquired by Clinical Data Inc.
Currently, she serves as Chairman of the Board and Acting CEO of
Cvergenx, Inc., a diagnostics services company that is developing
a genomics-based test to predict a patient’s sensitivity
to radiation therapy. She also serves on the Board of Intelomed,
Inc., a medical device company with a non-invasive platform technology
that measures the body’s physiological responses to stress
in real time for improved cardiovascular and fluid management.
|
|
Mary Del Brady
Co-Founder and
Board Director
|
|
|
|
|
| |
Mike Gausling, is the Managing
Director of Originate Venture Partners, a venture capital investment
firm targeting early stage companies in Pennsylvania and surrounding
regions with investments ranging from $1 million to $4 million.
Mike is the Co-founder and former CEO of OraSure Technologies
where he helped to build the company from a start-up to more
than $50 million in annual sales with a market cap of more than
$500 million over seventeen years. In that time, Mike has raised
more than $75 million from angel investors, venture capitalists,
public offerings, and commercial banks. Mike has held financial
management positions at Proctor & Gamble
and served as a Board member and Audit Chair at KNBT Bancorp.
Mike currently serves on the Life Science Advisory Board for Safeguard
Scientifics, Inc. and is Treasurer of LVIP, a non-profit land development
company in Bethlehem, PA.
|
|
Mike Gausling
Board Director
|
|
|
|
|
| |
John W. Manzetti was named President and Chief Executive Officer of PLSG in December 2006. John is also the
Managing Director of the PLSG Accelerator Fund, LLC, a for-profit venture capital fund managed by the PLSG. Prior to
joining the PLSG, Mr. Manzetti held the position of President and Chief Executive Officer at NOMOS Corporation, a leader in
the field of radiation therapy treatment solutions for solid cancer tumors. Mr. Manzetti holds a Bachelor of Science in Business
Administration and Honorary Doctorate of Entrepreneurial Business from Geneva College and an MBA from the University of Akron. |
|
John W. Manzetti
Board Director
|
|
|
|
|
| |
Larry Miller, Executive in Residence with Innovation
Works, collaborates with management teams of early stage life science
or medical device start-up technology companies. Larry has broad
experience in medical device and capital equipment marketing, sales
service and equipment finance. Prior to joining Innovation Works,
Larry was President and CEO of Biomec, a technology accelerator
and investment company which raised over $20M in SBIR grants. At
Picker International and Philips Medical systems, Larry was president
of the Healthcare Products group, a $ 600 million distributor of
radiology supplies, where he managed the Asia/ Pacific region for
sales and service of the diagnostic imaging product portfolio,
and was President of the Picker Financial Group. Other assignments
include marketing and sales of CT and MRI products for Picker and
General Electric Medical systems.
|
|
Larry Miller
Board Observer
|
|
|
|
|
| |
David S. Smith,
a corporate lawyer focusing on intellectual property transactions,
venture financings and regulatory matters for life sciences companies
and investors, is of counsel with Pepper Hamilton LLP. David
is founder and principal of Teregenics, LLC, providing strategic
product development analysis to investors, research centers and
companies developing human tissue engineering and regeneration
technologies. He was senior
vice president and general counsel of TissueInformatics.Inc and,
before that, of counsel at Reed Smith, LLP where he led the development
of that firm’s biotechnology practice. David is an
adjunct professor in Carnegie Mellon University’s Department
of Engineering and Public Policy, former member of the Scientific
Advisory Board of Clinical Cell Culture, trustee of AMD3 Research
Foundation, and serves on the executive committee of Tissue Engineering
and Regenerative Medicine International Society. |
|
David S. Smith
Board Secretary
|
|
|
|
|
| |
Gardiner F.H. Smith is President and Chief Executive Officer
of ThermalTherapeutic Systems (TTS). Mr. Smith joined TTS after guiding several life sciences startups through the Pittsburgh Life
Sciences Greenhouse Executive Program. Prior to joining the Greenhouse, Mr. Smith was CEO and founder of TenX Biopharma, a Phase III
cancer antibody company which was sold in May, 2011. He previously co-founded a consulting firm, SHI Link, of 8 professionals offering
biopharma and medical device management services, including his position as interim President of Nexeon MedSystems. Mr. Smith's
executive experience includes serving as the SVP of business development at Aspreva Pharmaceuticals, and as the Chief Business Officer,
Memory Pharmaceuticals Corp where he played a key role in a 2004 IPO, raising $35 MM, and a 2005 PIPE for $20 MM. At Memory he led
four major transactions in three and a half years, providing $60 MM in payments made to the company resulting in later acquisition.
As Executive Director, Business Development, at Human Genome Sciences Inc., Mr. Smith led multiple transactions with small and large
pharmaceutical companies. Mr. Smith also served as the Director, International Licensing, Glaxo Wellcome where he supported the oncology
therapeutic franchise and genomics directorate and led strategic alliances with industry and academic centers.
Education:1992 Juris Doctorate, North Carolina Central University; 1983 Bachelor's, Chemistry, University of North Carolina at Chapel Hill.
|
|
Gardiner F.H. Smith
Board Director
|
|
|
|
|
|
